A phase 2, randomized, double-blind, placebo-controlled, multicenter study of the safety and effects on lipids of 12 weeks of 2 doses of FM-VP4 in subjects with primary hypercholesterolemia
Latest Information Update: 03 Nov 2021
At a glance
- Drugs FM VP4 (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Forbes Medi-Tech
Most Recent Events
- 07 Oct 2006 New trial record.